Literature DB >> 34952469

Expression level of BTN3A1 on the surface of CD14+ monocytes is a potential predictor of γδ T cell expansion efficiency.

Mako Tomogane1, Maho Omura1, Yusuke Sano1, Daiki Shimizu1, Yuki Toda1, Shigekuni Hosogi1, Shinya Kimura2, Eishi Ashihara3.   

Abstract

Human γδ T cells expressing Vγ9Vδ2 T cell receptors exert a robust response to pathogens and malignant cells. These cells are activated by BTN3A1, which is expressed by pathogen-derived phosphoantigens (pAgs) or host-derived pAgs that accumulate in transformed cells or in cells exposed to aminobisphosphonates. Activated Vδ2 (+) T cells exert multiple effector functions; therefore, they are a promising candidate for immunotherapy. However, not all donors have γδ T cells with adequate proliferative activity. Here, we performed ex vivo culture of γδ T cells from 20 healthy donors and explored factors that may affect their expansion efficiency. Consistent with previous studies, we found that amplification of γδ T cells requires CD14+ monocytes to act as accessory cells. We also show here that surface expression of BTN3A1 by monocytes correlates positively with γδ T cell expansion. Moreover, treatment with BTN3A1-Fc increased the expansion efficiency of peripheral blood mononuclear cells (PBMCs) from donors harboring γδ T cells with poor expansion capacity. Taken together, the data suggest that the level of BTN3A1 expressed on the surface of monocytes is a useful biomarker for predicting the degree of expansion of γδ T cells.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BTN3A1; Monocytes; Vγ9Vδ2 T cells; γδ T cells

Mesh:

Substances:

Year:  2021        PMID: 34952469     DOI: 10.1016/j.bbrc.2021.12.060

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Generation of effector Vγ9Vδ2 T cells and evaluation of their response to phosphoantigen-loaded cells.

Authors:  Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  STAR Protoc       Date:  2022-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.